BOXED O
WARNING O
: O
WARNING O
: O
GASTROINTESTINAL O
PERFORATIONS O
, O
SURGERY O
AND O
WOUND O
HEALING O
COMPLICATIONS O
, O
and O
HEMORRHAGE O
WARNING O
: O
GASTROINTESTINAL O
PERFORATIONS O
, O
SURGERY O
AND O
WOUND O
HEALING O
COMPLICATIONS O
, O
and O
HEMORRHAGE O
EXCERPT O
: O
WARNING O
: O
GASTROINTESTINAL O
PERFORATIONS O
, O
SURGERY O
AND O
WOUND O
HEALING O
COMPLICATIONS O
, O
and O
HEMORRHAGE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Gastrointestinal O
Perforations O
: O
Discontinue O
for O
gastrointestinal O
perforation O
. O

( O
5.1 O
) O
* O
Surgery O
and O
Wound O
Healing O
Complications O
: O
Discontinue O
in O
patients O
who O
develop O
wound O
healing O
complications O
that O
require O
medical O
intervention O
. O

Withhold O
for O
at O
least O
28 O
days O
prior O
to O
elective O
surgery O
. O

Do O
not O
administer O
Avastin O
for O
at O
least O
28 O
days O
after O
surgery O
and O
until O
the O
wound O
is O
fully O
healed O
. O

( O
5.2 O
) O
* O
Hemorrhage O
: O
Severe O
or O
fatal O
hemorrhages O
have O
occurred O
. O

Do O
not O
administer O
for O
recent O
hemoptysis O
. O

Discontinue O
for O
Grade O
3-4 O
hemorrhage O
( O
5.3 O
) O
Gastrointestinal B-OSE_Labeled_AE
Perforations I-OSE_Labeled_AE
: O
The O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
in O
patients O
receiving O
Avastin O
ranges O
from O
0.3 O
% O
to O
3 O
% O
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Surgery O
and O
Wound B-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
Complications I-OSE_Labeled_AE
: O
The O
incidence O
of O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
and O
surgical O
complications I-OSE_Labeled_AE
, O
including O
serious O
and O
fatal B-NonOSE_AE
complications O
, O
is O
increased O
in O
patients O
receiving O
Avastin O
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
that O
require O
medical O
intervention O
. O

Withhold O
Avastin O
at O
least O
28 O
days O
prior O
to O
elective O
surgery O
. O

Do O
not O
administer O
Avastin O
for O
at O
least O
28 O
days O
after O
surgery O
, O
and O
until O
the O
wound O
is O
fully O
healed O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Hemorrhages B-NonOSE_AE
: O
Severe O
or O
fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
, O
including O
hemoptysis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
CNS B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
vaginal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
occur O
up O
to O
5-fold O
more O
frequently O
in O
patients O
receiving O
Avastin O
. O

Do O
not O
administer O
Avastin O
to O
patients O
with O
a O
recent O
history O
of O
hemoptysis B-Not_AE_Candidate
. O

Discontinue O
in O
patients O
who O
develop O
Grade O
3-4 O
hemorrhage B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

